Baxter estimates raised by Bear Stearns

Baxter International Inc. was reiterated by Bear Stearns analyst Rick Wise at an outperform rating with a price target on the stock of $45 per share following Baxter's win in the lawsuit against Abbott Laboratories to market a generic version of the anesthetic Ultane. While Bear Stearns believes the launch may still be difficult, it should help speed up growth for Baxter, and the firm's EPS estimated was raised to $2.15 from $2.11 for 2006. Baxter shares Monday were up $0.01, or 0.03%, at $39.96 on volume of 2,593,500 shares versus the three-month running average of 1,696,900 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.